Liver fibrosis test study for fatty liver disease
Part of Digestive system clinical trials.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have or are suspected to have fatty liver disease (like NAFLD, NASH, MASLD, or MASH).
- You are scheduled for a liver biopsy or had one in the past 6 months.
- Your age is between 18 and 75 years old.
- Your BMI is 45 or lower.
- You do not have other liver diseases (like hepatitis, alcoholic liver disease, or autoimmune hepatitis) or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how liver scarring (fibrosis) and fat buildup (steatosis) change over time in people with nonalcoholic fatty liver disease (NAFLD). It helps doctors understand risk factors so they can better predict and manage the disease.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
Hear when a new Non-alcoholic Fatty Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.